Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DNTH-103 by Dianthus Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
DNTH-103 is under clinical development by Dianthus Therapeutics and currently in Phase I for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According...